Cited by 188Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

Open access
Janelidze, Shorena, Palmqvist, Sebastian, Leuzy, Antoine, Stomrud, Erik, Verberk, Inge M.W., Zetterberg, Henrik, Ashton, Nicholas J., Pesini, Pedro +7 more·2022·Alzheimer's & Dementia

Abstract

Introduction: We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p‐tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD). Methods: Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) and immunoassays (p‐tau217 and NfL) in cognitively unimpaired individuals (CU, N = 591) and patients with mild cognitive impairment (MCI, N = 304) from two independent cohorts (BioFINDER‐1, BioFINDER‐2). Results: In CU, a combination of plasma Aβ42/Aβ40 and p‐tau217 detected abnormal brain Aβ status with area under the curve (AUC) of 0.83 to 0.86. In MCI, the models including p‐tau217 alone or Aβ42/Aβ40 and p‐tau217 had similar AUCs (0.86–0.88); however, the latter showed improved model fit. The models were implemented in an online application providing individualized risk assessments ( https://brainapps.shinyapps.io/PredictABplasma/ ). Discussion: A combination of plasma Aβ42/Aβ40 and p‐tau217 discriminated Aβ status with relatively high accuracy, whereas p‐tau217 showed strongest associations with Aβ pathology in MCI but not in CU.

Integrity signals

Registry

Crossref · 10.1002/alz.12395

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous research attempted to develop algorithms combining multiple factors and showed better and more robust performance in predicting Aβ positivity of Alzheimer's disease.

    “Previous research attempted to develop algorithms combining multiple factors and showed better and more robust performance in predicting Aβ positivity of Alzheimer’s disease.”
  • Detection of Aβ positivity using mass spectrometry %p-tau217 in cognitively normal cohorts appears better than what has been reported when using plasma p-tau217 immunoassays.

    “Detection of Aβ positivity using mass spectrometry %p-tau217 in cognitively normal cohorts appears better than what has been reported when using plasma p-tau217 immunoassays, although this must be confirmed in head-to-head studies22,23,48–50.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., Teunissen, C. E., Dage, J. L., Blennow, K., Mattsson‐Carlgren, N., & Hansson, O.
Affiliations
  • Lund University (SE)
  • Amsterdam Neuroscience (NL)
  • Sahlgrenska University Hospital (SE)
  • King's College London (GB)
  • Araclon Biotech Ltd. Zaragoza Spain
  • Eli Lilly (United States) (US)
  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö Lund University Lund Sweden
Corresponding author
Hansson, Oskar
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2021-06-20
Volume
18
Issue
2
Pages
283-293
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W3174265554
Cited by
188
References
14
Citations by year
2026: 16 · 2025: 49 · 2024: 53 · 2023: 40 · 2022: 27 · 2021: 3
FWCI
22.40
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Vetenskapsrådet (2016‐00906)
  • Knut och Alice Wallenbergs Stiftelse (2017‐0383)
  • Marianne and Marcus Wallenberg Foundation (2015.0125)
  • Hjärnfonden (FO2019‐0326)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
  • Alzheimer Nederland
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
early Alzheimer's disease, amyloid-beta
MeSH terms
Alzheimer Disease, Amyloid, Amyloidosis, Humans, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review